Search results for "POINT"

showing 10 items of 4385 documents

Diagnostic Yield of 2 Strategies for Adult Celiac Disease Identification in Primary Care

2017

Goals: To compare the diagnostic yield and cost-consequences of 2 strategies, screening regardless of symptoms versus case finding (CF), using a point-of-care test (POCT), for the detection of celiac disease (CD) in primary care, to bridge the diagnostic gap of CD in adults. Materials and Methods: All subjects under 75 years of age who consecutively went to their general practitioners’ offices were offered POCT for anti-transglutaminase immunoglobulin A antibodies. The POCT was performed on all subjects who agreed, and then a systematic search for symptoms or conditions associated with higher risk for CD was performed, immediately after the test but before knowing the test results. The 2 …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentCross-sectional studyPoint-of-care testingCost-Benefit AnalysisPrimary careDisease03 medical and health sciencesprimary careYoung Adult0302 clinical medicinecase findingInternal medicineMedicineHumansMass Screening030212 general & internal medicineYoung adultMedical diagnosisAgedAged 80 and overdiseaseTransglutaminasesPrimary Health Carebusiness.industryscreeningGastroenterologyceliaMiddle AgedImmunoglobulin Acase finding; celiac disease; point-of-care test; primary care; screening; GastroenterologyCeliac DiseaseCross-Sectional StudiesPoint-of-Care TestingCase finding030211 gastroenterology & hepatologyObservational studypoint-of-care testFemalebusiness
researchProduct

Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A …

2006

BACKGROUND: Desquamative gingivitis (DG) is a clinical condition characterized by red, painful, glazed, and friable gingiva, which might be a manifestation of some autoimmune mucocutaneous diseases. The time from the development of initial signs of DG to diagnosis can vary from months to years. Based on a literature search, no data concerning patients with DG without signs of autoimmune disease were available. OBJECTIVE: The aim of this trial was to compare the efficacy and tolerability of monotherapy with topical tacrolimus 0.1% in pectin ointment versus clobetasol propionate 0.5% ointment in adults affected by DG. METHODS: This randomized, double-blind clinical trial was conducted at the …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaErythemaAdministration TopicalPopulationSeverity of Illness IndexTacrolimuslaw.inventionOintmentsRandomized controlled trialDouble-Blind Methodlawdesquamative gingivitimedicineClinical endpointHumansPharmacology (medical)educationAgedPharmacologyeducation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseDermatologyGingivitisdesquamative gingivitisTacrolimusSurgeryDesquamative gingivitisTreatment OutcomeTolerabilityclobetasoltopical tacrolimus; clobetasol; desquamative gingivitis; randomized double-blind clinical trialtacrolimus clobetasol desquamative gingivitisPectinsDrug Therapy CombinationFemaleClobetasol propionatemedicine.symptombusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studiestopical tacrolimurandomized double-blind clinical trial
researchProduct

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

2015

The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial.Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m(2) on days 1, 8, and 15 every 4 weeks or dacarbazine 1000 mg/m(2) every 3 weeks. The primary end point was progression-free survival (PFS) by independent radiologic review; the secondary end point was overall survival (OS).A total of 529 patients were randomized to nab-paclitaxel (n = 264) or dacarbazine (n = 265). Baseline characteristics were well balanced. The majority of patients were men (66%), had an Eastern Cooperative Oncology Group status of 0 (7…

AdultMalemedicine.medical_specialtySkin NeoplasmsPaclitaxelDacarbazineGastroenterologyDisease-Free Survivallaw.inventionYoung AdultRandomized controlled triallawInternal medicineAlbuminsmedicineClinical endpointHumansProgression-free survivalAntineoplastic Agents AlkylatingMelanomaAgedAged 80 and overbusiness.industryMelanomaHazard ratioHematologyOriginal ArticlesMiddle Agedmedicine.diseaseChemotherapy regimenConfidence intervalSurgeryDacarbazineOncologyFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

2021

Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monotherapy in first-line non-small-cell lung cancer. Here, we present the primary analysis data of cemiplimab in patients with locally advanced basal cell carcinoma after HHI therapy. Methods We did an open-label, multicentre, single-arm, phase 2 trial across 38 outpatient clinics, primarily at academic medical centres, in Canada, Europe, and the USA. Eligible patients (aged ≥18 years…

AdultMalemedicine.medical_specialtySkin NeoplasmsPyridinesProgrammed Cell Death 1 ReceptorVismodegibAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaClinical endpointOutpatient clinicHumansBasal cell carcinomaAnilidesHedgehog ProteinsLung cancerImmune Checkpoint InhibitorsAgedbusiness.industryStandard treatmentMiddle Agedmedicine.diseaseRegimenOncologyCarcinoma Basal CellDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drugThe Lancet. Oncology
researchProduct

Endovascular therapy for vasospasm after aneurysmatic subarachnoid hemorrhage

2016

Balloon angioplasty and/or selective intra-arterial vasodilator therapies are treatment options in patients with vasospasm after subarachnoid hemorrhage (SAH). We analyzed the effect of balloon angioplasty and/or selective intra-arterial vasodilator therapy in our patients.Twenty-six patients (vasodilation group, VDT) were treated with intra-arterial nimodipine. The balloon angioplasty with nimodiopine-group (BAP-N group) comprised 21 patients. The primary endpoint of this study was successful angiographic vessel dilation in vasospastic vessels after balloon angioplasty, together with nimodipine (BAP-N group), compared to intra-arterial vasodilator therapy (VDT group) with nimodipine alone.…

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageVasodilator Agentsmedicine.medical_treatmentCerebral arteriesVasodilationBalloon030218 nuclear medicine & medical imaging03 medical and health sciencesPostoperative Complications0302 clinical medicineInternal medicineAngioplastymedicineClinical endpointHumansVasospasm IntracranialNimodipineAgedRetrospective Studiesbusiness.industryEndovascular ProceduresVasospasmGeneral MedicineCerebral ArteriesMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseTreatment OutcomeInjections Intra-ArterialAnesthesiaCardiologyFemaleNimodipineSurgeryPatient SafetyNeurology (clinical)businessAngioplasty Balloon030217 neurology & neurosurgerymedicine.drugBritish Journal of Neurosurgery
researchProduct

The Intracranial Distribution of Gliomas in Relation to Exposure From Mobile Phones: Analyses From the INTERPHONE Study

2016

When investigating the association between brain tumors and use of mobile telephones, accurate data on tumor position are essential, due to the highly localized absorption of energy in the human brain from the radio-frequency fields emitted. We used a point process model to investigate this association using information that included tumor localization data from the INTERPHONE Study (Australia, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Sweden, and the United Kingdom). Our main analysis included 792 regular mobile phone users diagnosed with a glioma between 2000 and 2004. Similar to earlier results, we found a statistically significant association …

AdultMalemedicine.medical_specialtyTELEPHONENeoplasms Radiation-InducedTime FactorsEpidemiologyOriginal ContributionsTumor burdenBrain tumorAudiologyMOBILE TELEPHONES03 medical and health sciences0302 clinical medicinePhoneRisk FactorsRecall biasEXPOSITION AU RISQUECERVEAUMedicineHumans030212 general & internal medicineEpidemiologic researchSelf reportONDERADIO-FREQUENCY ELECTROMAGNETIC FIELDSbusiness.industryBrain NeoplasmsINTERPHONE STUDYMiddle Agedmedicine.diseaseTumor BurdenMobile phone030220 oncology & carcinogenesisEpidemiologic Research DesignGLIOMAFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieSPATIAL POINT PATTERNNeoplasm GradingbusinessINTRACRANIAL DISTRIBUTIONCell PhoneTUMEUR
researchProduct

Localization of Muscle Edema and Changes on Muscle Contractility After Dry Needling of Latent Trigger Points in the Gastrocnemius Muscle.

2019

Background Myofascial trigger points (TrPs) are hyperirritable spots within taut bands of skeletal muscles that elicit local and referred pain when stimulated. Among the variety of techniques used for treating TrPs, dry needling (DN) is the most commonly applied intervention. The physiological mechanisms underlying the effects of DN remain to be elucidated. Objective To examine changes in skeletal muscle after DN in the area where the TrP is located. Methods We measured in vivo changes that occur in human skeletal muscle one hour after DN over a TrP with magnetic resonance imaging (MRI) and tensiomyography. The study included 18 asymptomatic subjects with a latent TrP in one medial gastrocn…

AdultMalemedicine.medical_specialtyTensiomyographyContractility03 medical and health sciencesGastrocnemius muscleYoung Adult0302 clinical medicineEdemaInternal medicinemedicineEdemaHumansMuscle SkeletalDry needlingmedicine.diagnostic_testbusiness.industrySkeletal muscleTrigger PointsMagnetic resonance imaging030229 sport sciencesGeneral MedicineMuscle stiffnessMagnetic Resonance ImagingAnesthesiology and Pain Medicinemedicine.anatomical_structureEndocrinologyDry NeedlingNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgeryMuscle ContractionPain medicine (Malden, Mass.)
researchProduct

Results of the performance verification of the CoaguChek XS system.

2008

Abstract Background This is the first paper reporting a performance verification study of a point-of-care (POC) monitor for prothrombin time (PT) testing according to the requirements given in chapter 8 of the International Organization for Standardization (ISO) 17593:2007 standard “Clinical laboratory testing and in vitro medical devices — Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy”. The monitor under investigation was the new CoaguChek XS system which is designed for use in patient self testing. Its detection principle is based on the amperometric measurement of the thrombin activity generated by starting the coagulation cascade using a rec…

AdultMalemedicine.medical_specialtyTime FactorsCoefficient of variationPoint-of-Care SystemsThromboplastinYoung AdultCoagulation cascadeAcceptance testingReference ValuesmedicineHumansIn patientInternational Normalized RatioBlood testingBlood CoagulationOral anticoagulationAgedReagent StripsProthrombin timeAged 80 and overmedicine.diagnostic_testbusiness.industryAnticoagulantsHematologyMiddle AgedRecombinant ProteinsSurgerySelf CareOral anticoagulantProthrombin TimeFemaleDrug MonitoringbusinessBiomedical engineeringThrombosis research
researchProduct

Optimal Response to Cardiac Arrest study: Defibrillation waveform effects

2001

Abstract Introduction: Advances in early defibrillation access, key to the “Chain of Survival”, will depend on innovations in defibrillation waveforms, because of their impact on device size and weight. This study compared standard monophasic waveform automatic external defibrillators (AEDs) to an innovative biphasic waveform AED. Material and methods: Impedance-compensated biphasic truncated exponential (ICBTE) and either monophasic truncated exponential (MTE) or monophasic damped sine (MDS) AEDs were prospectively, randomly assigned by date in four emergency medical services. The study design compared ICBTE with MTE and MDS combined. This subset analysis distinguishes between the two clas…

AdultMalemedicine.medical_specialtyTime FactorsEndpoint DeterminationDefibrillationmedicine.medical_treatmentElectric CountershockEmergency NursingReturn of spontaneous circulationhemic and lymphatic diseasesInternal medicineIntensive careHumansMedicineChain of survivalCardiopulmonary resuscitationAutomated external defibrillatorAgedAged 80 and overbusiness.industryEquipment DesignMiddle Agedmedicine.diseaseSurvival AnalysisCardiopulmonary ResuscitationDefibrillators ImplantableHeart ArrestSurgeryEuropeTreatment OutcomeShock (circulatory)Ventricular fibrillationEmergency MedicineCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessResuscitation
researchProduct

Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multi…

2008

Summary Background Carotid stenting is a potential alternative to carotid endarterectomy but whether this technique is as safe as surgery and whether the long-term protection against stroke is similar to that of surgery are unclear. We previously reported that in patients in the Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial, the rate of any stroke or death within 30 days after the procedure was higher with stenting than with endarterectomy. We now report the results up to 4 years. Methods In this follow-up study of a multicentre, randomised, open, assessor-blinded, non-inferiority trial, we compared outcome after stenting with outcome …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCarotid endarterectomyRisk AssessmentSeverity of Illness IndexFunctional LateralityDouble-Blind MethodRisk FactorsInternal medicineAngioplastyClinical endpointConfidence IntervalsMedicineHumansCarotid StenosisLife Tablescardiovascular diseasesLongitudinal StudiesStrokeEndarterectomyAgedProportional Hazards ModelsRetrospective StudiesEndarterectomy Carotidbusiness.industryHazard ratioAngioplastyMiddle Agedmedicine.diseaseSurgeryStrokeStenosisTreatment OutcomeCardiologyFemaleNeurology (clinical)Carotid stentingbusinessThe Lancet. Neurology
researchProduct